Abstract
The roles of reactive astrocytes in Alzheimer's disease (AD) and the correlation between plasma glial fibrillary acidic protein (GFAP) and amyloid-β are emerging. Among 133 patients with cognitive complaints from multi-center memory clinics in Thailand, 73 had AD as defined either by cerebrospinal fluid core biomarkers or amyloid PET. Plasma GFAP demonstrated an AUC of 0.74 (95%CI: 0.65–0.83) for detecting AD and showed large effects on identifying AD status with Cohen's d = 0.81 (95%CI 0.44–1.18). LOESS regression illustrated that plasma GFAP increased from the early stages of AD. Plasma GFAP has potential applications across diverse populations.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
